Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Abivax SA American Depositary Shares

Healthcare US ABVX

94.0525USD
-4.3775(4.45%)

Last update at 2026-06-24T18:15:00Z

Day Range

74.7998.42
LowHigh

52 Week Range

5.59148.83
LowHigh

Fundamentals

  • Previous Close 98.43
  • Market Cap9361.04M
  • Volume5808653
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-244.98301M
  • Revenue TTM4.57M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM 4.57M
  • Diluted EPS TTM-5.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -320.15995M -176.24200M -152.23300M -74.32300M -45.56100M
Minority interest - - - - -
Net income -322.83696M -176.24200M -147.74000M -69.84600M -41.35700M
Selling general administrative 72.86M 32.95M 28.11M 49.61M 44.97M
Selling and marketing expenses - 5.95M 0.71M - -
Gross profit -1.02969M 10.79M 4.57M -0.11000M 0.04M
Reconciled depreciation 1.07M 1.10M 0.71M 0.31M 0.16M
Ebit -240.73351M -172.98300M -133.91400M -56.75700M -42.53500M
Ebitda -239.70381M -171.88300M -133.20700M -56.44800M -42.37900M
Depreciation and amortization 1.03M 1.10M 0.71M 0.31M 0.16M
Non operating income net other - - - - -
Operating income -240.73351M -172.98400M -127.37600M -56.64500M -42.56000M
Other operating expenses 240.73M 183.78M 131.95M 56.65M 42.60M
Interest expense 27.39M 4.18M 13.83M 3.70M 3.15M
Tax provision 5.85M 0.00000M 0.00000M -4.47600M -4.20400M
Interest income 5.75M 8.96M 2.77M 0.13M 0.08M
Net interest income -52.48600M -4.56400M -12.74900M -3.80600M -3.12600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.68M - -4.49300M -4.47600M -4.20400M
Total revenue 0.00000M 10.79M 4.62M 0.00000M 0.04M
Total operating expenses 239.70M 183.78M 127.38M 56.54M 42.60M
Cost of revenue 1.03M - 0.71M 0.11M 0.00000M
Total other income expense net -79.42645M -3.25800M -20.36400M -17.67800M -3.00100M
Discontinued operations - - - - -
Net income from continuing ops -336.10200M -176.24200M -147.74000M -69.84700M -41.35700M
Net income applicable to common shares - - - -60.74000M -42.45200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 584.09M 205.23M 327.06M 73.35M 110.36M
Intangible assets 6.60M 6.61M 6.60M -13.13800M -0.64700M
Earning assets - - - - -
Other current assets 10.36M 10.79M 5.88M - 5.73M
Total liab 129.08M 164.64M 131.05M 64.65M 74.75M
Total stockholder equity 455.01M 40.58M 196.01M 8.70M 35.61M
Deferred long term liab - - - - -
Other current liab 61.69M 0.53M 37.43M 3.08M 2.65M
Common stock 0.78M 0.63M 0.63M 0.22M 0.17M
Capital stock 0.79M 0.63M 0.63M 0.22M 0.17M
Retained earnings -738.16770M -438.87900M -282.94900M -148.75400M -78.90800M
Other liab - - - 1.22M 10.72M
Good will 18.41M 18.42M 18.42M 36.66M 32.74M
Other assets - -0.00100M - 12.74M 1.34M
Cash 516.47M 144.22M 251.94M 26.94M 60.70M
Cash and equivalents - - - - -
Total current liabilities 62.99M 92.83M 70.04M 28.04M 21.21M
Current deferred revenue - - 0.05M - -
Net debt -484.38576M -46.86000M -196.47800M 19.12M -7.24300M
Short term debt 1.30M 43.77M 10.61M 9.49M 0.00700M
Short long term debt - 42.84M 10.23M 9.49M 0.00700M
Short long term debt total 32.08M 97.36M 55.46M 46.07M 53.45M
Other stockholder equity 1190.09M 478.90M 478.22M 157.23M 114.35M
Property plant equipment - - - 1.59M 0.30M
Total current assets 551.01M 170.67M 285.97M 48.19M 75.21M
Long term investments 0.00000M 0.13M 0.12M - -
Net tangible assets - - - -17.83700M -6.16400M
Short term investments 13.69M 0.14M 9.05M 0.00600M 0.00600M
Net receivables 10.49M 15.66M 19.10M 8.32M 1.47M
Long term debt - 52.16M 44.70M 36.58M 53.45M
Inventory - - 0.00000M - 4.00M
Accounts payable 37.55M 43.82M 21.95M 15.47M 18.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.31M -0.07500M 0.11M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.98M 6.74M -3.71100M 1.24M 2.75M
Deferred long term asset charges - - - - -
Non current assets total 33.08M 34.56M 41.09M 25.16M 35.15M
Capital lease obligations 1.86M 2.36M 0.54M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 15.76M -8.09500M -0.51300M -1.45600M
Change to liabilities - - - -2.41400M 1.10M
Total cashflows from investing activities -13.18139M 15.76M - -12.02600M -6.23200M
Net borrowings -59.53300M 37.49M - -9.80100M 19.14M
Total cash from financing activities 531.94M 28.21M 340.57M 48.03M 78.51M
Change to operating activities - - - - -
Net income -322.83696M -176.24200M -147.74000M -37.63300M -42.56000M
Change in cash 389.36M -107.72100M 224.99M 19.53M 31.40M
Begin period cash flow 127.10M 251.94M 26.95M 9.77M 29.30M
End period cash flow 516.47M 144.22M 251.94M 29.30M 60.70M
Total cash from operating activities -155.69178M -154.07200M -100.00900M -27.98900M -45.65700M
Issuance of capital stock 648.12M 0.43M 353.39M 28.59M 65.47M
Depreciation 1.03M 1.10M 0.71M 0.31M 0.16M
Other cashflows from investing activities 0.07M 16.40M - -8.79000M -4.00900M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - - 2.08M -
Change to account receivables 6.76M 4.59M -14.23100M 0.31M -4.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.58689M -9.71300M -28.05700M 11.37M -10.29800M
Change to netincome - - - 8.32M -2.23000M
Capital expenditures 0.14M 0.64M 0.27M 0.04M 1.64M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.51M 1.42M 21.27M 7.22M -1.41400M
Stock based compensation 35.40M 20.22M 8.18M -1.16400M 0.83M
Other non cash items 162.61M -0.57700M 9.65M -0.24000M -1.83900M
Free cash flow -155.82818M -154.71500M -100.27500M -28.03200M -47.29900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABVX
Abivax SA American Depositary Shares		 -4.3775 4.45% 94.05 - - 2048.37 17.02 157.63 -12.6604
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Abivax SA American Depositary Shares

7-11 Boulevard Haussmann, Paris, France, 75009

Key Executives

Name Title Year Born
Mr. Marc M. P. de Garidel M.B.A. CEO & Interim Chair of Board 1958
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director 1958
Mr. Didier Blondel EVP, CFO & Board Secretary 1964
Mr. Didier Scherrer Ph.D. Chief Scientific Officer 1970
Mr. Patrick Malloy Senior Vice President of Investor Relations NA
Ms. Ida Hatoum Chief People Officer 1975
Mr. Pierre Courteille M.B.A. Chief Business Officer 1969
Mr. Jérôme Denis Executive Vice President of Process Development & Manufacturing NA
Mr. Sheldon Sloan M.D. Chief Medical Officer 1959
Mr. Michael Ferguson B.S., M.B.A. Chief Commercial Officer 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions